Notice of Annual General Meeting of Biovitrum AB, 28 April 2009
In accordance with the listing agreement with NASDAQ OMX Stockholm
AB, Biovitrum AB (publ) hereby announces, also by issuing a press
release, the content of the notice concerning Biovitrum's Annual
General Meeting on 28 April 2009, and the complete proposal from the
Board of Directors regarding the performance based, long-term share
program for 2009 comprising proposal regarding a directed issue of
series C shares and proposal regarding authorization for the board of
directors to repurchase issued series C shares.
Attachments:
- Notice of Biovitrum's Annual General Meeting 2009
- Proposal from the Board of Directors regarding the performance
based, long-term share program for 2009 comprising proposal regarding
a directed issue of series C shares and proposal regarding
authorization for the board of directors to repurchase issued series
C shares
For further information please contact:
Martin Nicklasson, CEO
Phone: +46 8 697 25 45
Göran Arvidson, CFO
Cell phone: +46 70 633 30 42
Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com
About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets a
range of specialist pharmaceuticals internationally. Using its
expertise and experience Biovitrum takes scientific innovation all
the way to the market and to specialist indication patients with
significant medical need. Research expertise and capabilities are
focused on development and production of biotechnology therapeutics
within our prioritized areas of hemophilia, inflammation/autoimmune
diseases and malabsorption. The company has revenues of approximately
SEK 1.1 billion and around 400 employees. It is listed on the OMX
Nordic Exchange in Stockholm. For more information go to
www.biovitrum.com.